Source:http://linkedlifedata.com/resource/pubmed/id/17827386
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
13
|
| pubmed:dateCreated |
2007-12-6
|
| pubmed:abstractText |
A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 microg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow har-vest. Median nucleated (NC) and CD34 cells infused was 6.7 x 10(8)/kg (range, 2.4-18.5 x 10(8)/kg) and 7.4 x 10(6)/kg (range, 2-27.6 x 10(6)/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32%) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13%) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81% and 69%, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:AyasMouhabM,
pubmed-author:BillheimerDeanD,
pubmed-author:ColeCatherineC,
pubmed-author:FrangoulHaydarH,
pubmed-author:GruppStephan ASA,
pubmed-author:KhanShakilaS,
pubmed-author:LevineJohn EJE,
pubmed-author:ManesBeckyB,
pubmed-author:NemecekEneida RER,
pubmed-author:PulsipherMichael AMA,
pubmed-author:RavindranathYaddanapudiY,
pubmed-author:WaltersMark CMC,
pubmed-author:WoolfreyAnnA
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
110
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4584-7
|
| pubmed:meshHeading |
pubmed-meshheading:17827386-Adolescent,
pubmed-meshheading:17827386-Adult,
pubmed-meshheading:17827386-Antigens, CD34,
pubmed-meshheading:17827386-Bone Marrow,
pubmed-meshheading:17827386-Bone Marrow Transplantation,
pubmed-meshheading:17827386-Cell Count,
pubmed-meshheading:17827386-Child,
pubmed-meshheading:17827386-Child, Preschool,
pubmed-meshheading:17827386-Graft Survival,
pubmed-meshheading:17827386-Graft vs Host Disease,
pubmed-meshheading:17827386-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:17827386-Hematopoietic Stem Cells,
pubmed-meshheading:17827386-Humans,
pubmed-meshheading:17827386-Infant,
pubmed-meshheading:17827386-Kinetics,
pubmed-meshheading:17827386-Prospective Studies,
pubmed-meshheading:17827386-Survival Analysis,
pubmed-meshheading:17827386-Transplantation, Homologous
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study.
|
| pubmed:affiliation |
Department of Pediatrics, Vanderbilt University, Nashville, TN 37232-2573, USA. haydar.frangoul@vanderbilt.edu
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|